Thomas Ollila

1.0k total citations
45 papers, 375 citations indexed

About

Thomas Ollila is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Thomas Ollila has authored 45 papers receiving a total of 375 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Pathology and Forensic Medicine, 19 papers in Oncology and 15 papers in Genetics. Recurrent topics in Thomas Ollila's work include Lymphoma Diagnosis and Treatment (29 papers), Chronic Lymphocytic Leukemia Research (13 papers) and CAR-T cell therapy research (9 papers). Thomas Ollila is often cited by papers focused on Lymphoma Diagnosis and Treatment (29 papers), Chronic Lymphocytic Leukemia Research (13 papers) and CAR-T cell therapy research (9 papers). Thomas Ollila collaborates with scholars based in United States, Spain and Canada. Thomas Ollila's co-authors include Adam J. Olszewski, John L. Reagan, İlyas Şahin, Adam Zayac, Shaolei Lu, Ralph Rogers, James N. Butera, Rabin Niroula, Ari Pelcovits and Patrycja M. Dubielecka and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Thomas Ollila

36 papers receiving 372 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Ollila United States 9 202 177 85 76 70 45 375
Michael A. Spinner United States 10 218 1.1× 276 1.6× 39 0.5× 49 0.6× 31 0.4× 35 481
Shankara Paneesha United Kingdom 11 154 0.8× 186 1.1× 44 0.5× 154 2.0× 77 1.1× 39 434
Sai Ravi Pingali United States 14 113 0.6× 212 1.2× 51 0.6× 64 0.8× 57 0.8× 63 529
Jay E. Gold United States 13 151 0.7× 235 1.3× 67 0.8× 60 0.8× 30 0.4× 21 418
Mariëlle J. Wondergem Netherlands 12 136 0.7× 96 0.5× 33 0.4× 53 0.7× 21 0.3× 37 331
Wu‐Ching Uen Taiwan 8 137 0.7× 174 1.0× 67 0.8× 53 0.7× 71 1.0× 10 502
Nelofar Shafi United States 10 149 0.7× 157 0.9× 35 0.4× 54 0.7× 20 0.3× 16 311
Umberto Tirelli Italy 11 230 1.1× 336 1.9× 57 0.7× 53 0.7× 105 1.5× 23 471
Andrés López Spain 8 382 1.9× 302 1.7× 87 1.0× 97 1.3× 13 0.2× 16 498
Byeong-Bae Park South Korea 11 110 0.5× 184 1.0× 19 0.2× 34 0.4× 56 0.8× 24 431

Countries citing papers authored by Thomas Ollila

Since Specialization
Citations

This map shows the geographic impact of Thomas Ollila's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Ollila with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Ollila more than expected).

Fields of papers citing papers by Thomas Ollila

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Ollila. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Ollila. The network helps show where Thomas Ollila may publish in the future.

Co-authorship network of co-authors of Thomas Ollila

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Ollila. A scholar is included among the top collaborators of Thomas Ollila based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Ollila. Thomas Ollila is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Olszewski, Adam J., Narendranath Epperla, Dai Chihara, & Thomas Ollila. (2023). IMMUNOTHERAPY ALONE VERSUS CHEMOIMMUNOTHERAPY AS FIRST‐LINE TREATMENT OF MARGINAL ZONE LYMPHOMA (MZL): A REAL‐WORLD ANALYSIS. Hematological Oncology. 41(S2). 107–108. 1 indexed citations
4.
Trabolsi, Asaad, Narendranath Epperla, Lindsey Fitzgerald, et al.. (2023). A Multicenter Study Analyzing Survival and Prognostic Factors in Patients with Leukemic Phase Follicular Lymphoma. Blood. 142(Supplement 1). 3770–3770. 1 indexed citations
5.
Pelcovits, Ari, Thomas Ollila, & Adam J. Olszewski. (2023). Advances in Immunotherapy for the Treatment of Cutaneous T-Cell Lymphoma. Cancer Management and Research. Volume 15. 989–998. 5 indexed citations
6.
Ollila, Thomas, et al.. (2023). Correlation between PFS and OS in FL: Implications for Clinical Trial Endpoint Selection. Blood. 142(Supplement 1). 4395–4395. 1 indexed citations
7.
Ollila, Thomas, et al.. (2023). Immunochemotherapy or chemotherapy alone in primary central nervous system lymphoma: a National Cancer Database analysis. Blood Advances. 7(18). 5470–5479. 1 indexed citations
8.
Olszewski, Adam J., Thomas Ollila, Ari Pelcovits, et al.. (2023). Alterations in Immune Cell Composition during First-Line Therapy with Mosunetuzumab for Follicular or Marginal Zone Lymphoma. Blood. 142(Supplement 1). 1651–1651.
9.
Marin, Benjamin Gallo, et al.. (2022). Drug‐induced hypersensitivity syndrome and eosinophils in skin biopsy in a patient with pancytopenia. American Journal of Hematology. 98(4). 697–699.
10.
11.
Ollila, Thomas & Adam J. Olszewski. (2021). Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma. Cancer Management and Research. Volume 13. 3935–3952. 8 indexed citations
12.
Olszewski, Adam J., Anna Chorzalska, Thomas Ollila, et al.. (2020). Cerebrospinal Fluid (CSF) Analysis of Tumor-Specific Cell-Free DNA (cfDNA) As a Diagnostic and Prognostic Tool for Central Nervous System (CNS) Invasion in Lymphoma. Blood. 136(Supplement 1). 21–22. 5 indexed citations
13.
Bakow, Brianna R., Christopher P. Elco, Mark LeGolvan, Don S. Dizon, & Thomas Ollila. (2020). Molecular Profiles of Brain and Pulmonary Metastatic Disease in Cancer of Unknown Primary. The Oncologist. 25(7). 555–559. 1 indexed citations
14.
15.
Olszewski, Adam J., Anna Chorzalska, Diana O. Treaba, et al.. (2019). Tumor-Specific Cell-Free DNA (cfDNA) in the Cerebrospinal Fluid (CSF) Detects Cytologically Occult Central Nervous System (CNS) Involvement in Aggressive Lymphomas. Blood. 134(Supplement_1). 2800–2800. 1 indexed citations
16.
Olszewski, Adam J., Thomas Ollila, & John L. Reagan. (2019). Bendamustine-Rituximab Does Not Improve Survival over Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma. Blood. 134(Supplement_1). 2824–2824. 3 indexed citations
17.
Ollila, Thomas, İlyas Şahin, & Adam J. Olszewski. (2019). <p>Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma</p>. OncoTargets and Therapy. Volume 12. 1085–1094. 55 indexed citations
18.
19.
Ollila, Thomas & Adam J. Olszewski. (2018). Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence. Current Treatment Options in Oncology. 19(8). 38–38. 97 indexed citations
20.
Ollila, Thomas, Syed Naeem, Athena Poppas, George R. McKendall, & Afshin Ehsan. (2016). Embolization of Inferior Vena Cava Filter Tyne and Right Ventricular Perforation: A Cardiac Missile. The Annals of Thoracic Surgery. 102(6). e515–e516. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael A. Spinner Breakdown of academic impact, for papers by Shankara Paneesha Breakdown of academic impact, for papers by Sai Ravi Pingali Breakdown of academic impact, for papers by Jay E. Gold Breakdown of academic impact, for papers by Mariëlle J. Wondergem Breakdown of academic impact, for papers by Wu‐Ching Uen Breakdown of academic impact, for papers by Nelofar Shafi Breakdown of academic impact, for papers by Umberto Tirelli Breakdown of academic impact, for papers by Andrés López Breakdown of academic impact, for papers by Byeong-Bae Park
Rankless by CCL
2026